21423259

Source:http://linkedlifedata.com/resource/pubmed/id/21423259

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0017596, umls-concept:C0021390, umls-concept:C0041582, umls-concept:C1122087, umls-concept:C2825407
pubmed:issue	5
pubmed:dateCreated	2011-6-21
pubmed:abstractText	Antibodies that target tumor necrosis factor are effective at inducing and maintaining remission in both Crohn's disease (infliximab, adalimumab and certolizumab) and ulcerative colitis (infliximab). The results of a randomized controlled trial of adalimumab for inducing remission in moderately to severely active ulcerative colitis have now been published.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/21423259-21209123
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/101500079
pubmed:status	PubMed-not-MEDLINE
pubmed:month	May
pubmed:issn	1759-5053
pubmed:author	pubmed-author:ArmuzziAlessandroA, pubmed-author:PuglieseDanielaD
pubmed:issnType	Electronic
pubmed:volume	8
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	249-51
pubmed:year	2011
pubmed:articleTitle	IBD: Adalimumab for ulcerative colitis— is the glass half empty or half full?
pubmed:affiliation	Internal Medicine and Gastroenterology Unit, Complesso Integrato Columbus, Catholic University, Via Moscati 31, Rome, Italy. alearmuzzi@yahoo.com
pubmed:publicationType	Journal Article, Comment